Phio Pharma Shares Are Moving Higher On INTASYL Preclinical Data At ESMO Presentation

Phio Pharmaceuticals Corp PHIO has announced preclinical results from a new study of a self-delivering RNAi (INTASYL) therapeutic platform.
The data were presented at the European Society of Medical Oncology (ESMO) Congress 2021.
The study was performed to show the synergistic activity of co-targeting PD-1 and BRD4 with one INTASYL formulation (PH-3861) in a preclinical in vivo hepatocellular carcinoma (liver cancer) model.
The results show that up to 83% of the animals treated with PH-3861 had a complete response at low doses.
The treatment induced a durable and specific systemic antitumor immune response without requiring further treatment.
Related Link: Phio Pharma's PH-762 Shows Encouraging Antitumor Efficacy In Preclinical Studies.
Price Action: PHIO stock is up 18.80% at $2.34 during the premarket session on the last check Thursday.
Check out our coverage of the European Society for Medical Oncology Congress (ESMO21)